ACTRN12624000570583尚未招募2 期
Effect of subcutaneous (sc) semaglutide on gastric emptying of, and the postprandial glycaemic and cardiovascular responses to, a carbohydrate meal in people with type 2 diabetes.
niversity of Adelaide0 个研究点目标入组 32 人开始时间: 2024年5月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 40 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Male or female participants aged 40 – 80 years
- •Female subjects who are post-menopausal; or pre-menopausal with surgical contraception (such as tubal ligation) or an intrauterine device. Pre-menopausal women will require a confirmed negative urine ß-hCG pregnancy test at screening visit.
- •T2DM (World Health Organisation (WHO) criteria) managed by diet alone or on metformin
- •Glycated haemoglobin (HbA1c) greater than or equal to 6.0% and less than or equal to 8.5%, in the last 4 months prior to enrolment in the study
- •Body mass index (BMI) 25 – 40 kg/m2
- •Haemoglobin and ferritin in the normal range for gender and age.
- •Participant has provided written informed consent.
排除标准
- •Evidence of renal disease (i.e. a creatinine clearance cut-off of < 50 ml/min. Calculated creatinine clearance will be determined as follows using the Cockcroft-Gault equation: Cr clearance = [140 - age (years) x weight (kg)] / [0.814 x serum creatinine (µmol/L)] (For female subjects, multiply Cr clearance x 0.85)(24)
- •Iron stores, or liver function tests outside the following ranges:
- •Alanine aminotransferase (ALT)< 55 U/L
- •Alkaline phosphatase (ALP)30 - 110 U/L
- •Aspartate transaminase (AST)< 45 U/L
- •Total bilirubin6 - 24 µmol/L
- •Haemoglobin115 – 155 g/L (Females)
- •135 – 172 g/L (Males)
- •Ferritin15 – 200 µg/L (Females)
- •30 – 300 µg/L (Males)
- •Hepatic or cardiovascular disease, pancreatitis (subjects with past history of acute or chronic pancreatitis, gastric surgery, or known gastroparesis on history or screening biochemistry tests.
- •Participants with any history of cancer, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy = 12 months prior to screening or other malignancies treated with apparent success with curative therapy = 5 years prior to screening will be excluded.
- •History of any clinically significant disease or disorder which may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer’s ability to participate in the study.
- •Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- •History of hyperthyroidism or uncontrolled hypothyroidism.
- •Chronic gastrointestinal symptoms as assessed by questionnaire.
- •Use of drugs potentially affecting gastrointestinal motility (corticosteroids; anti-emetics (dopamine antagonists, 5HT-3 receptor antagonists), laxatives, prokinetic agents, anticholinergic agents, cholinergic agents, opioid medications, erythromycin).
- •Current use of anticoagulants.
- •Inability to abstain from smoking for 12 hours prior to the gastric emptying tests.
- •Consumption of greater than 2 units alcohol daily on a regular basis.
- •Known or suspected history of alcohol or drug abuse, as judged by the Investigator.
- •History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to semaglutide or drugs with a similar chemical structure or its components.
- •Known hypersensitivity to IV infusion equipment, plastics, adhesive or silicone, or know history of hypotension or infusion site reactions with IV administration of other medicines
- •Participation in any research studies involving exposure to ionising radiation exceeding 2.5mSv in the previous 12 months
- •Donated blood in the past 3 months
- •Vegetarian
研究者
相似试验
进行中（未招募）
1 期
Research study looking at how well semaglutide works in people suffering from obesity and knee osteoarthritisMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesityEUCTR2020-000204-11-DKovo Nordisk A/S375
进行中（未招募）
1 期
Research study looking at how well semaglutide works in people suffering from obesity and knee osteoarthritisMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesityEUCTR2020-000204-11-FRovo Nordisk A/S375
进行中（未招募）
1 期
Research study looking at how well semaglutide works in people suffering from obesity and knee osteoarthritisMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesityEUCTR2020-000204-11-NOovo Nordisk A/S375
进行中（未招募）
1 期
Research study looking at how well semaglutide works in people suffering from obesity and knee osteoarthritisMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesityEUCTR2020-000204-11-SEovo Nordisk A/S375
进行中（未招募）
1 期
Research study looking at how well semaglutide works in people living with obesity and prediabetesMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesityEUCTR2020-002939-29-FIovo Nordisk A/S201